Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | MARS1 | P56192 | 7/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252769 | 0.88 | FASN (0.44) | CNR1MGLL | |
| SCHEMBL25292260 | 0.84 | PTGS2 (0.48) | RAB9A | |
| SCHEMBL25256703 | 0.84 | PTGS2 (0.43) | CNR1KMT2A | |
| SCHEMBL29497024 | 0.83 | RET (0.43) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL25254039 | 0.83 | RET (0.43) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL23211853 | 0.82 | SCD5 (0.45) | CNR2NPC1RAB9A | |
| SCHEMBL30700130 | 0.80 | MGLL (0.49) | CNR1ALPLCNR2MGLL | |
| SCHEMBL25257284 | 0.78 | KMT2A (0.42) | MARS1SRD5A2ALPLMEN1KMT2A | |
| SCHEMBL29497108 | 0.75 | MGLL (0.38) | CNR1MARS1ALPLCNR2MGLL | |
| SCHEMBL5236075 | 0.75 | CNR2 (0.54) | CNR1CNR2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | CNR1 136/4885MARS1 1800/4885SRD5A2 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.